Small Cell Lung Cancer
Small Cell Lung Cancer
Advertisement
Cecilia BrownNon-Small Cell Lung Cancer | July 24, 2024
The initiative aims to increase biomarker testing rates in communities most impacted by lung cancer disparities.
Read More
Cecilia BrownSmall Cell Lung Cancer | July 22, 2024
The novel B7-H3–targeting antibody-drug conjugate has a novel payload.
Katie KoskoASCO 2024: Focus on Lung Cancer | July 5, 2024
More than half of patients in the study had psychological distress as well as elevated serum cortisol levels.
Leah LawrenceASCO 2024: Focus on Lung Cancer | July 2, 2024
Study investigators say the results support further study of the bispecific T-cell engager in previously treated SCLC.
Katie KoskoASCO 2024: Focus on Lung Cancer | June 20, 2024
The study showed that patients with certain types of insurance had significantly shorter overall survival.
Cecilia BrownAdvancements in Oncology | June 16, 2024
Dr. Rami Manochakian and The Oncology Brothers discusses treatment for SCLC, which is evolving at a rapid pace.
David R. Spigel, MDASCO 2024: Focus on Lung Cancer | June 6, 2024
Dr. Spigel discusses the implications of ADRIATIC at the 2024 American Society of Clinical Oncology Annual Meeting.
Cecilia BrownASCO 2024: Focus on Lung Cancer | June 4, 2024
The median investigator-assessed PFS was 5.7 months in patients who received bevacizumab plus ACE.
Cecilia BrownASCO 2024: Focus on Lung Cancer | June 3, 2024
The ADRIATIC results were presented during a plenary session at the 2024 American Society of Clinical Oncology Meeting.
Cecilia BrownSmall Cell Lung Cancer | May 30, 2024
Researchers aimed to address the limited data on combining a PD-L1 inhibitor with chemotherapy in older adults.
Cecilia BrownLung Cancer | May 28, 2024
Exposures to substances such as Agent Orange are "not currently addressed in prevailing risk models."
Cecilia BrownSmall Cell Lung Cancer | May 20, 2024
The treatment is the first and only bispecific T-cell engager therapy for advanced SCLC.
Cecilia BrownSmall Cell Lung Cancer | May 17, 2024
Global clinical trials are scheduled to begin after IND approval is received for phase 2 trials in the US and Europe.
Cecilia BrownLung Cancer | May 15, 2024
The primary end point of the RESILIENT trial was OS.
Kaitlyn KoskoSmall Cell Lung Cancer | April 19, 2024
The timing of chemotherapy given to patients with SCLC does not have a statistically significant impact on OS.
Kaitlyn KoskoSmall Cell Lung Cancer | April 18, 2024
The timing of chemotherapy given to patients with SCLC does not have a statistically significant effect on OS.
Mary GreccoSmall Cell Lung Cancer | March 26, 2024
Chemotherapy-induced myelosuppression among patients with extensive-stage SCLC is poorly understood.
Mary GreccoSmall Cell Lung Cancer | March 26, 2024
The DeLLphi-301 study that evaluated patients with advanced SCLC.
Mary GreccoSmall Cell Carcinoma | March 22, 2024
Lurbinectedin monotherapy is currently being studied in Jazz EMERGE 402 study in patients with metastatic SCLC.
Kaitlyn KoskoSmall Cell Lung Cancer | February 27, 2024
Researchers from the US and Italy have identified a biomarker that can distinguish between SCLC and SCC.
Advertisement
Advertisement
Advertisement
Latest News

July 26, 2024